摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
A compound of the formula (I) in which R1 is —OR11, —SR11, —SOR11, —SO2R11, —NHR11, or —NR12R13 , and R11, R12, and R13 are as defined broadly in the text. R2 is H, C1-C6alkyl, carbamoyl, or an ester group. R3 is thienyl, pyridyl optionally substituted by halogen or C1-C6alkoxy; naphthyl optionally substituted by C1-C6alkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.
摘要翻译:其中R 1为-OR 11,-SR 11,-SOR 11的式(I)化合物, SO 2,-SO 2,R 11,-NHR 11或-NR 12 R 13 < / SUP>和R 11,R 12和R 13如在文中广义地定义的。 R 2是H,C 1 -C 6烷基,氨基甲酰基或酯基。 R 3是噻吩基,任选被卤素或C 1 -C 6烷氧基取代的吡啶基; 任选被C 1 -C 6烷氧基取代的萘基; 二恶烷稠合苯基; 二氧杂环戊烷稠合苯基; 或任选取代的苯基。 Y是CH或N.一种制备这种化合物的方法,含有这些化合物的药物组合物和使用它们治疗哮喘的方法也被公开和要求保护。
摘要:
4-aryl pyrimidine compounds of general formula and salts thereof: wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxycarbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.
摘要:
Pyridine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33, or —NR34R35; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
摘要:
Pyridine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents 1.2.3.6-tetrahydro-pyridine, or —CR31R32R33 wherein R31 represents H or C1-6 alkyl and R32 and R33 are joined to form a 5-8 membered saturated ring optionally containing up to three heteroatoms; R4 is carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
摘要翻译:吡啶化合物,其通式如下:其中R 1表示其中R 11为氢,C 1-6烷基,卤素,羟基,C 1-12烷氧基,硝基,氨基,C 1-6烷基磺酰基氨基,C 1-6烷氧基羰基,C 1-6烷基, (C 1-6烷基)氨基,C 1-6烷酰基氨基,苯基C 1-6烷基氨基,苯基磺酰基氨基,C 1 -C 6烷基氨基, ,或-O-(CH 2)n - n - R 111; R 2表示氢或卤素; R 3表示1.2.3.6-四氢 - 吡啶或-CR 31,其中R 1,R 2,R 3, SUP> 31表示H或C 1-6烷基,R 32和R 33连接形成5-8 任选地含有至多三个杂原子的饱和环; R 4是氨基甲酰基,CN,羧基等; R 5是氨基,C 1-6烷基氨基,C 1-6烷基氨基等,或其盐。 该化合物具有优异的抗炎活性和其他生物活性。
摘要:
This invention is to provide a process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs and salts thereof, comprising the reaction shown by the following scheme. The ester analogs can be prepared in one pot, and in good yield by using tertiary alkyl cyanoacetate. Furthermore, the method is useful for preparing derivatives of various analogs of the ester, e.g. alkyl substituted and aryl substituted analogs.
摘要:
Pyrimidine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
摘要翻译:其中R 1表示其中R 11为氢,C 1-6烷基,卤素,羟基,C 1 -C 6烷基, 1-12烷氧基,硝基,氨基,C 1-6烷基磺酰基氨基,C 1-6烷氧基羰基,C 1-6烷基, (C 1-6烷基)氨基,C 1-6烷酰基氨基,苯基C 1-6烷基氨基,苯基磺酰基氨基,C 1 -C 6烷基氨基, ,或-O-(CH 2)n - n - R 111; R 2表示氢或卤素; R 3表示氢,-CR 31,32,32,33, R 4是氢,氨基甲酰基,CN,羧基等; R 5是氨基,C 1-6烷基氨基,C 1-6烷基氨基等,或其盐。 该化合物具有优异的抗炎活性和其他生物活性。
摘要:
The invention described herein provides a mixture comprising polymer molecules or salts thereof, wherein a polymer molecule in the mixture comprises covalently bound subunits L, K, and M wherein the average molecular weight of the polymer molecules in the mixture is about 50 kDa to about 200 kDa, wherein the mole percentage of subunit M, K and L, relative to the total amount of subunits in the mixture, is about 90.5 to about 96 mol %, about 2.8 to about 7.3 mol %, and about 1.2 to about 2.2 mol %, respectively.